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Abstract
In classic Hairy cell leukaemia (HCLc), a single case has thus far been interrogated by
whole exome sequencing (WES) in a treatment naive patient, in which BRAF V(600)E was
identified as an acquired somatic mutation and confirmed as occurring near-universally in
this form of disease by conventional PCR-based cohort screens. It left open however the
question whether other genome-wide mutations may also commonly occur at high fre-
quency in presentation HCLc disease. To address this, we have carried out WES of 5 such
typical HCLc cases, using highly purified splenic tumour cells paired with autologous T cells
for germline. Apart from BRAF V(600)E, no other recurrent somatic mutation was identified
in these HCLc exomes, thereby excluding additional acquired mutations as also prevalent
at a near-universal frequency in this form of the disease. These data then place mutant
BRAF at the centre of the neoplastic drive in HCLc. A comparison of our exome data with
emerging genetic findings in HCL indicates that additional somatic mutations may however
occur recurrently in smaller subsets of disease. As mutant BRAF alone is insufficient to
drive malignant transformation in other histological cancers, it suggests that individual
tumours utilise largely differing patterns of genetic somatic mutations to coalesce with
BRAF V(600)E to drive pathogenesis of malignant HCLc disease.
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Introduction
Hairy cell leukaemia (HCL) is a rare B-cell neoplasia with a distinctive morphology, displaying
extensive cytoplasmic projections that give the disease its name [1–2]. It presents in the main
as a typical or classic form of disease (HCLc) that can be distinguished from the atypical or var-
iant HCL subtype (HCLv) by the specific immunophenotypic markers CD25, CD123, and
ANXA-1. The HCLv subtype accounts for ~10% of all HCL disease cases, and differs in disease
behaviour, associating more frequently with refractory response to therapy [1–3]. It is as yet
not fully known how these differing HCL disease forms arise, and whether the precise molecu-
lar and cellular pathways that drive the pathogenesis of HCLc and HCLv disease subtypes are
related or vary markedly.
In early work on HCL origins, we as well as others probed this question by focusing on anal-
ysis of immunoglobulin (Ig) heavy chain variable region (IGHV) genes. Ig variable domains are
crucial in recognising antigen via the B-cell receptor (BCR), and these domains are specifically
encoded by rearranged IGHV genes paired with rearranged light chain variable region (IGVL)
genes [4]. The germline repertoire of IGHV genes alone comprises several families based on
shared homology (IGHV1 to IGHV7), and each family comprises varying numbers of gene seg-
ments which are referred to in notation depending on locus distribution (e.g. gene segment 34
as IGHV4-34 in family IGHV4) [5]. Across HCL disease, where tumours are invariably mono-
clonal, the repertoire of tumour-derived IGHV gene use is varied and compared with the nor-
mal B-cell repertoire, use of IGHV3-21, IGHV3-30 and IGHV3-33 appears elevated suggesting
possible selection pressure of antigen on the cell of origin in this malignancy [6]. Regarding
IGHV gene usage, ~10% of HCLc cases utilise the IGHV4-34 gene (hereafter referred to as
HCLc-IGHV4-34 cases), and importantly use of the IGHV4-34 gene segment specifically asso-
ciates with a poorer outcome of disease and suboptimal response to therapy [7]. These insights
from IGHV gene usage implicate distinctive pathways in clonal origins in HCL.
The nature of oncogenic events that drive malignant transformation in HCL had until
recently received scant genome-wide attention. Seminal insights have emerged first in HCLc
disease. In this subset, a mutation in BRAF V(600)E was identified in whole exome sequencing
(WES) of a single typical case at disease presentation [8], and due to the known prominence of
this mutation more broadly in cancer, led to its selection and verification by conventional PCR-
based screens in a larger number of HCLc tumours to establish it as a signature genetic mutation
in this disease subtype [8,9,10]. Although these studies confirmed the occurrence of BRAFV
(600)E as near universal in HCLc disease, interestingly and in marked contrast, in HCLv and in
the unusual HCLc-IGHV4-34 cases, BRAF V(600)E was found to be invariably absent suggest-
ing segregated pathways in the origins of these different forms of HCL disease [11,12]. It left
open however the question of the nature of driver mutation(s) in the atypical HCL subtypes.
More recently this question has been resolved to a large extent. Waterfall et al carried out
WES of 10 HCLv and HCLc-IGHV4-34 cases, and in theseMAP2K1mutations emerged as a
common somatic variant (SV) [13]. By examiningMAP2K1mutations more broadly by stan-
dard Sanger protocols, the overall frequency of mutations inMAP2K1 was identified as 48% in
a panel of HCLv/HCLc-IGHV4-34 tumours (n = 21) [13].MAP2K1mutations were however
rare in typical HCLc that lacked the IGHV4-34 gene, to separate disease subsets based on the
acquisition of distinctive somatic mutations [13]. TheMAP2K1mutation yielding a p.Cys121-
Ser coding shift was the most common in the combined HCLv/HCLc-IGHV4-34 tumour
panel, andMAP2K1mutations associated with predicted constitutive enzymatic activity [13].
Apart fromMAP2K1, other gene mutations were far less common in HCLv/HCLc-IGHV4-34
exomes [13], indicating that theMAP2K1mutation is dominant and a driver in atypical HCL
origins and progression (i.e. in HCLv/HCLc-IGHV4-34 tumours).
HCLc ExomeMutations
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These recurrent gene mutations in classic and atypical HCL disease highlight specific cellu-
lar signalling conduits in disease origins. In its wild type form, the BRAF gene encodes the
BRAF serine/threonine kinase which phopsphorylates and activates its substrates MEK1/2, and
thereby transduces signals via the RAS-RAF-MEK-ERK mitogen-activated protein kinase
(MAPK) pathway [14]. In this signalling pathway, MEK1 (also known as MAPKK1, mitogen-
activated protein kinase kinase 1) is encoded by theMAP2K1 gene [15]. BRAF andMAP2K1
genes have emerged as commonly mutated in HCLc or atypical HCL respectively.
In attempting to correlate exome findings in HCLc with atypical disease further however, a
marked limitation emerged, as thus far only a single exome has been analysed in presentation
HCLc disease [8]. This left open the question whether other mutation(s) might also occur
across the genome that are recurrent, in addition to BRAF V(600)E. Additional common driver
mutations in typical HCLc tumours appeared highly probable, given the findings that although
the BRAF V(600)E mutation is an early founder event in both benign melanocytic naevi and
pre-malignant colonic polyps, it is nevertheless insufficient for full malignant transformation
in these tumours [16]. These considerations suggested a possibility that additional driver(s)
events may be required to synergise with BRAF V(600)E to progress malignant transformation
in typical HCLc, that would require identification at a genome-wide level. To address this, we
have carried out WES in 5 typical HCLc cases, in each comparing tumour exome with matched
germline.
Materials and Methods
Patient Samples
Ethics. Ethical approval for the study was obtained from institutional bodies. The HCLc
samples were obtained by Professor H. Kluin-Nelemans in the Department of Hematology,
University Medical Center Groningen, Netherlands, and provided for study use approved
under Ethical Review by the National Research Ethics Service Committee South Central
(Southampton A) Reference M228/02/t (Amendment 7). The HCLc samples comprise an
existing holding collected in 1980–1990 and for which consent is waived by the Human Tissue
Authority. The University of Southampton UK holds Human Tissue Authority licence 12009.
Samples. Typical HCL disease was diagnosed by clinical criteria, bone marrow and spleen
histology, neoplastic cell morphology, cytochemical analysis and immunophenotype [17] (and
Table 1). Following splenectomy, splenic lymphocytes were disaggregated and stored in liquid
N2 until use. After thawing, samples were resuspended in complete RPMI medium (cRPMI)
(RPMI 1640, 20% foetal calf serum, 1 mM sodium pyruvate MEM, 0.1 mMMEM non-essential
amino acids, 2 mM L-glutamine (Gibco Invitrogen, Paisley, UK)) and allowed to stabilise at
37°C in 5% CO2 for at least 1 h prior to use. Viability was assessed by trypan blue exclusion.
Immunophenotyping
Multiparameter flow cytometric immunophenotype was performed as described previously
[18], with sIg expression analysed on CD19+CD11cHI or CD19+CD11cHICD103+ HCL cells
(Table 1). Additional markers were assessed using CD25-PE (BD Biosciences, Oxford, UK),
CD27-PE (BD) and CD123-PE (BD) antibodies on CD19+CD11cHICD103+ cells (Table 1).
Data were analysed using FACSDiva (BD) and FlowJo (Tree Star Inc., Ashland, OR, USA).
ANXA1 detection was performed as previously described [19]. Briefly, ANXA1 was detected
either by western blot or immunocytochemistry using the antibody ‘Purified mouse anti-
Annexin I’, clone 29/Annexin I (BD Transduction Laboratories, Oxford, UK) (Table 1).
HCLc ExomeMutations
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IGHV analysis
IGHV sequencing was performed as reported previously [20], using IMGT V-QUEST (http://
www.imgt.org/IMGT_vquest/vquest?livret=0&Option=humanIg) for IGHV donor germline
gene derivation (Table 1). None of the HCLc cases utilised IGHV4-34 germline IGHV gene,
and all tumours uniformly exhibited somatically hypermutated IGHV rearranged genes.
FACS purification of HCL tumour cells and germline T cells
HCL samples were stained for CD19-eFluor450 (eBioscience, Hatfield, UK)/CD19-V450 (BD),
CD11c-APC (BioLegend, London, UK), CD103-FITC (BioLegend/BD), CD27-APC-eFluor780
(eBioscience) and CD3-PE (BD/eBioscience) as described for immunophenotyping. HCLc
tumour cells were sorted and selected as a CD19+CD11cHICD103+CD27- population and
germline T cells from the same sample as CD3+ using the FACS Aria I (BD) (Fig 1). Sorted
populations were re-analysed for purity on the FACS Aria I: purity of HCLc sorts was 92.9–
98.3% and of T cells 96.7–100% (Fig 1 is a typical example). Data were analysed using FACS
Diva (BD) and FlowJo (TreeStar).
Table 1. Tumour characteristics of classic Hairy cell leukaemia cases analysed by whole exome sequencing. ND: not done. Surface immunopheno-
type, IGHV gene use and% homology to germline was determined as reported [17,18,19].
Tumour Surface immunophenotype %
tumour
sIg expression IGHV % Homology
to germline
BRAF V
(600)E#
Sanger
Purity post-sort
CD19 CD11c CD103 CD27 CD123 CD25 ANXA1 HCLc T
3T + + + - ND + ND 83 G+++M++κ+++ 3–30 96.10% + 92.90% 98.60%
5T + + + - ND ND ND 80 A+++G+++M+κ++λ+++ 3–15 92.20% + 98.20% 96.80%
9T + + + - ND ND ND 65 A+++D+++G+++M+++κ+++ 3–30 92.70% + 97.80% 96.70%
S4 + + + - + + + 71 D+++λ++ 3–30 96.90% + 98.30% 99.2%
S6 + + + - + + + 65 D+++λ++ 3–7 94.10% + 97.80% 99.0%
#BRAF V(600)E mutation was ﬁrst conﬁrmed in each case by conventional Sanger sequencing as we have described previously [18, 19].
doi:10.1371/journal.pone.0149162.t001
Fig 1. Gating strategy in flow cytometry to purify HCLc tumour cells andmatched germline T cells.
Splenocytes were stained with anti-CD19-eFluor450, anti-CD3-PE, anti-CD11c-APC, anti-CD27-APC-
eFluor780 and anti-CD103-FITC prior to sorting on the FACSAria. The plots show sorting on a representative
HCLc case.A: displays pre-sorted mononuclear cells, with CD19+CD11c+CD103+CD27- HCLc tumour cells
78.0% of sample and CD3+ T cells 3.3%. Cells were initially gated on FSC/SSC (A, left) then either CD3+ for
T cells or CD19+ for B cells (A, second left). CD19+ cells were subsequently gated as CD11c+ (A, second
right), then CD103+ and CD27- (A, right) to capture high purity HCL cells. In B post-sorted cells were
checked for purity: T cells were purified at 97.3% (left panel) and HCLc cells purified at 98.2% (right, three
panels). Data is representative of cell fraction isolation in each of 5 samples.
doi:10.1371/journal.pone.0149162.g001
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Genomic DNA extraction
Genomic DNA was immediately extracted from sorted HCLc and T cell populations respec-
tively using the DNeasy Blood and Tissue kit (Qiagen, Crawley, UK), according to the manu-
facturer’s protocol. Extracted DNA concentration was assessed by spectrophotometry
(NanoDrop ND1000, Labtech, Uckfield, UK) and the DNA stored at -20°C until use. HCLc
DNA was initially used to verify the BRAF V600E mutation by conventional PCR and Sanger
sequencing (Table 1) as we have reported previously [19].
Sanger Sequencing to Verify Somatic Variants
>30% of identified somatic variants (SVs) were selected at random for validation by PCR
amplification (primers available on request) and capillary Sanger sequencing (Tables 2 & 3). 50
ng DNA was used in multiplex PCRs with 35 cycles of 95°C for 30 s, 58°C for 30 s, 72°C for 1.5
mins. T cell germline DNA was used as control. PCR products were separated by electrophore-
sis on a 2% w/v agarose gel and extracted from excised bands using Qiagen gel extraction kit,
and subjected to Sanger sequencing using BigDye Terminator v1.1 with the AB3130xl Genetic
Analyser (both Applied Biosystems, Life Technologies, Paisley, UK). Data were analysed using
MacVector (Accelrys, San Diego, CA, USA) and 4Peaks software (Mek&Tosj, Amsterdam, The
Netherlands).
Whole Exome Sequencing
Genomic DNA from HCLc tumour cells and T cells for germline was analysed by WES. Whole
exome enrichment was performed with either Agilent SureSelect (50 Mb) (Agilent technolo-
gies, CA, USA) or Roche NimbleGen (44.1 Mb) (Roche NimbleGen, WI, USA). The resulting
exome libraries were sequenced on the Illumina HiSeq platform with paired-end 100 bp reads
to an average depth of 120-134x and with 88–90% of the target bases being covered by 20 or
more reads, which is sufficient for confident SV calling (Tables 3 & 4). Sample contamination
was estimated to be less than 3% and 0.5% when libraries were prepared using NimbleGen and
SureSelect respectively.
Exome sequence reads were deposited as bam files (accession no. E-MTAB-4313) to the
public database ArrayExpress (www.ebi.ac.uk/arrayexpress).
Table 2. Non-synonymous somatic variants identified in HCLc tumour exomes.
Sample Total *Known *Novel #Unﬂagged Validated
3T 19 7 12 10 5
5T 32 6 26 22 4
9T 14 7 7 7 4
S4 34 18 16 10 1
S6 19 12 7 4 2
Total 118 50 68 53 16
*Known and *Novel indicate presence or absence of SV respectively in the following databases: dbSNP135, 1000 genomes, Complete Genomics 46, the
NHLBI GO Exome Sequencing Project, and an in-house database of 279 non-cancer exomes.
#Unﬂagged variants are located outside of repetitive DNA and have not been observed at a frequency of 10% in any of 61 germline exomes as
determined by inspection in the interactive genome viewer.
doi:10.1371/journal.pone.0149162.t002
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Table 3. Novel nonsynonymous somatic variants identified in HCLc exomes from paired germline analysis. Annotations: COSMIC Catalogue of
Somatic Mutations in Cancer; Novel = not present in dbSNP135, 1000 genomes, Complete Genomics 46, the NHLBI GO Exome Sequencing Project), and
an in-house database of 279 non-cancer exomes. Functional predictions: PolyPhen-2.
Sample Gene Nucleotide Amino acid Waterfall
et al [13]
COSMIC Germline
mutant
reads (%)
Tumour
mutant
reads (%)
Somatic p-
value
Functional
prediction
Validated
3T BRAF A>T p.V600E p.V600E Y** 5 (2.45) 81 (48.21) 5.37x10-28 Possibly
deleterious
n
3T ZFP36L1 T>A p.L17F, p.
L86F
X* 3 (1.76) 52 (40.94) 3.27x10-19 Possibly
deleterious
y
3T CREBBP G>A p.P1072L, p.
P1110L
p.C1383fs X* 1 (0.54) 53 (31.36) 1.74x10-18 Probably
deleterious
y
3T DMXL2 T>C p.E471G, X** 5 (3.11) 60 (42.25) 4.18x10-18 Neutral y
3T DDX56 C>T p.R387H, p.
R427H
X* 1 (1.12) 31 (41.89) 6.69x10-12 Deleterious n
3T #CNTNAP4 G>A p.E555K X* 1 (1.05) 30 (38.46) 1.99x10-11 Neutral y
3T GMNC G>A p.S81F X 1 (0.95) 32 (28.07) 1.40x10-9 Deleterious y
3T CNOT10 G>A p.E559K, p.
E499K
X* 1 (2.38) 22 (62.86) 2.58x10-9 Possibly
deleterious
n
3T DUSP2 G>A p.Q274X X* 1 (1.64) 10 (21.28) 9.66x10-4 Probably
deleterious
n
3T LCA5 T>A p.D677V X* 1 (2.08) 10 (23.26) 2.066x10-3 Neutral n
5T STARD4 T>C p.T12A Y 1 (0.33) 115 (42.59) 1.51x10-43 Neutral n
5T BRAF A>T p.V600E p.V600E Y** 3 (1.35) 82 (50.31) 1.47x10-33 Possibly
deleterious
n
5T PEX1 C>T p.R1208Q X** 7 (3.63) 71 (39.23) 6.77x10-19 Neutral n
5T FOXA1 G>T p.Y207X X* 2 (1.54) 47 (47.96) 9.23x10-19 Probably
deleterious
y
5T KBTBD7 C>T p.R133H Y 0 (0) 50 (45.45) 3.79x10-18 Deleterious y
5T FAT3 G>C p.R3306T X* 0 (0) 36 (52.94) 7.21x10-15 Neutral n
5T POLD2 G>A p.Q5X,
Q40X
X* 1 (0.84) 44 (36.97) 1.18x10-14 Probably
deleterious
y
5T NCKAP1 T>A p.I188F, p.
I182F
X* 1 (0.40) 33 (14.54) 1.38x10-10 Neutral n
5T ABCC1 C>A p.S667Y X* 0 (0) 30 (25.00) 3.47x10-10 Neutral y
5T MAP1A G>T p.E108X X** 0 (0) 26 (13.20) 5.03x10-9 Probably
deleterious
n
5T KIAA1755 T>C p.E440G p.R897H Y 0 (0) 12 (37.50) 9.11x10-8 Neutral n
5T SDHAF2 C>T p.P54S Y 0 (0) 17 (20.00) 1.23x10-7 Deleterious n
5T LAPTM5 C>T p.C13Y X* 1 (0.65) 18 (13.85) 4.49x10-6 Possibly
deleterious
n
5T MAGEC3 T>G p.I279S X** 0 (0) 16 (11.59) 8.06x10-6 Probably
deleterious
n
5T CDKN1B C>G p.T198R Y 0 (0) 15 (19.48) 1.30x10-5 Deleterious n
5T ACTB G>A p.H73Y X* 0 (0) 11 (31.43) 1.96x10-5 Possibly
deleterious
n
5T SLC22A24 A>G p.L202P Y 0 (0) 15 (10.42) 3.03x10-5 n
5T SPATA5L1 G>A p.D6N, Y 1 (2.94) 23 (38.98) 4.70x10-5 Neutral n
5T MAPK15 G>A p.G351D X* 0 (0) 10 (30.30) 8.44x10-5 Probably
deleterious
n
5T TMSB4X G>A p.A8T Y 0 (0) 11 (13.58) 3.17x10-4 Neutral n
5T FAM108B1 T>A p.Y130F X* 1 (1.33) 13 (15.12) 1.385x10-3 Deleterious n
5T TAF3 G>C p.D467H X* 0 (0) 9 (15.00) 1.939x10-3 Deleterious n
(Continued)
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Table 3. (Continued)
Sample Gene Nucleotide Amino acid Waterfall
et al [13]
COSMIC Germline
mutant
reads (%)
Tumour
mutant
reads (%)
Somatic p-
value
Functional
prediction
Validated
9T SLC22A8 T>G p.T353P, p.
T444P, p.
T321P
Y 0 (0) 63 (48.84) 4.63x10-25 Deleterious y
9T BRAF A>T p.V600E p.V600E Y** 6 (3.39) 78 (44.32) 1.15x10-21 Possibly
deleterious
n
9T OGFOD1 C>A p.P495T Y 1 (0.74) 59 (44.36) 7.56x10-21 Deleterious y
9T ATP1A4 C>G p.R431G X* 0 (0) 29 (30.21) 4.16x10-10 Deleterious y
9T GRHL1 A>G p.S95G Y 1 (1.61) 30 (41.67) 4.25x10-9 Neutral n
9T C17orf80 C>T p.H257Y Y 0 (0) 27 (38.03) 2.61x10-8 Deleterious y
9T RASL12 C>A p.E54X Y 0 (0) 19 (13.57) 6.54x10-7 Probably
deleterious
n
4 CHD7 G>A p.R1189H Y* 0 (0) 104 (47.49) 4.20x10-39 Deleterious n
S4 SCD5 C>T p.R247H Y 1 (0.44) 74 (39.57) 1.10x10-28 Probably
deleterious
n
S4 BRAF A>T p.V600E p.V600E Y** 0 (0) 65 (49.24) 3.01x10-28 Possibly
deleterious
n
S4 CLEC6A A>G p.H165R Y 2 (1.13) 55 (47.83) 1.84x10-24 Deleterious n
S4 DUSP27 G>A p.S567N X* 0 (0) 37 (60.66) 1.82x10-19 Neutral n
S4 ZFP36 C>T p.S34F X* 0 (0) 25 (31.25) 1.81x10-10 Possibly
deleterious
y
S4 ZFYVE21 G>A p.V165M Y 0 (0) 25 (44.64) 2.14x10-10 Neutral n
S4 NUDT6 A>C p.V160G Y 0 (0) 21 (24.71) 1.32x10-9 Deleterious n
S4 TPPP2 A>T p.I39F Y 0 (0) 20 (45.45) 1.25x10-7 Possibly
deleterious
n
S4 ISX G>A p.G12D X* 0 (0) 10 (40.00) 1.68x10-4 Neutral n
S6 BRAF A>T p.V600E p.V600E Y** 1 (0.68) 43 (55.84) 9.29x10-24 Possibly
deleterious
n
S6 CRYBB1 G>A p.P27S Y 0 (0) 7 (31.82) 1.16x10-4 Deleterious y
S6 ADIPOR2 C>T p.R331W X* 0 (0) 6 (17.14) 3.452x10-3 Deleterious y
S6 MUC5B C>T p.P2096L p.V5587I X* 0 (0) 4 (10.00) 1.9875x10-2 Neutral n
#Gene: listed as a possible false positive [25]. COSMIC: Y = mutation is reported; X = mutation is not present but other somatic mutations are listed in this
gene in COSMIC.
*COSMIC: gene contains a mutation that occurs in haematopoietic and lymphoid tissue.
**COSMIC: gene contains a mutation that occurs in hairy cell leukaemia.
doi:10.1371/journal.pone.0149162.t003
Table 4. Average exome sequence coveragemetrics from paired HCLc exomes.
Germline Tumour
Total 100 bp read sequences 111,243,578 101,835,369
Mapped to target 78,593,158 69,852,536
Mapped to target (%) 70.7 68.3
Mapped to target +/-150 bp (%) 90.2 87.4
Mean coverage 133.7 119.5
Target bases with coverage >20 (%) 89.6 87.9
doi:10.1371/journal.pone.0149162.t004
HCLc ExomeMutations
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Bioinformatics
Raw exome sequence data, in the form of FASTQ sequence files, for paired germline and tumour
samples were aligned to the reference genome sequence (hg19) using NovoAlignMPI (v3.0). The
aligned data were quality controlled by using Picard tools (v1.34) to remove duplicate reads
(optical or PCR), unmapped reads, reads mapping to more than one location, and reads failing
vendor QC. Coverage statistics were calculated by using BEDTools (v2.13.2) [21] to assess the
quality controlled aligned data. For variant calling, SAMtools (v0.01.18) [22] was initially used
to create a ‘pileup’ up of reads in each germline and tumour sample. Somatic variants (SVs) were
then identified by using VarScan (v2.3.3) [23] to compare the tumour and normal pileup files
and ensure that the absence of germline variation was not due to low sequence coverage. For var-
iant calling using VarScan, the ‘somatic’, ‘somaticFilter’, and ‘processSomatic’ commands were
used with default parameters which required6 reads in the germline, a germline variant fre-
quency5%,8 reads in the tumour,3 reads with the variant allele, at least one mutant read
on the positive and negative strand, and a tumour variant frequency of10%. Somatic p-values
were determined by using a Fisher's Exact test to compare variant frequencies in tumour versus
germline and a threshold of p0.05 was used to select SVs with high confidence.
ANNOVAR [24] was used to annotate the SVs with respect to the gene they occur in, any
amino acid changes they cause, and whether they are listed in databases of known variation
(dbSNP135, 1000 genomes, Complete Genomics 46, the NHLBI GO Exome Sequencing Proj-
ect), and an in-house database of 279 non-cancer exomes. This information was used to select
novel nonsynonymous SVs for further scrutiny.
To minimise artefactual findings, genes were excluded if they had been identified as possible
false positives due to errors in sequence alignment [25] and they were flagged if they had low
expression and/or late replication, which are features that have been associated with high rates
of somatic mutation [26]. In addition, SVs occurring within or adjacent to repetitive DNA or
homopolymers were flagged. As a final check of data quality, the interactive genome viewer
[27] was used to inspect the novel SVs and to compare them with germline exomes (n = 61).
The novel SVs were also flagged if the same variant was observed at a frequency of10% in
any of the germline exomes. All unflagged SVs are shown in Table 3 and counts of flagged and
unflagged SVs are shown in Table 2.
The functional significance of variants was determined by using PolyPhen-2 (Polymor-
phism Phenotyping v2.2.2r398) [28].
To determine whether genes with high confidence SVs showed enrichment of biological
function we applied the Gene Functional Classification Tool (http://david.abcc.ncifcrf.gov) to
form functionally related groups of genes based on functional data from 14 annotation catego-
ries which include Gene Ontology (GO), KEGG Pathways, and OMIM [29].
To investigate copy number changes, VarScan was used to make preliminary copy number
calls and circular binary segmentation using the DNAcopy [30] library from BioConductor
was used to merge adjacent segments of similar copy number. Segments with log ratios0.7 or
-2 were compared across samples to search for regions with recurrent copy number changes.
To assess sample contamination, the non-reference variant calls from SAMtools were used
to calculate the ratio of heterozygous to homozygous genotypes in each tumour-normal pair
and to estimate the level of contamination by comparison with allele frequency information
from the 1000 genomes project [31].
Results
Firstly, we established that each of the 5 typical HCLc cases evaluated in this study displayed
uniform disease subtype features. All cases exhibited mutated BRAF V(600)E and imprints of
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somatic hypermutation (SHM) in IGHV genes as determined by standard Sanger sequencing
(Table 1). None of the HCLc cases expressed the rearranged Ig IGHV4-34 gene (Table 1).
Based on the distinctive HCLc immunophenotype, CD19+CD11c+CD103+CD27- tumour
cells were purified by flow cytometry and matched CD3+CD19- germline T cells flow-sorted
from splenocytes, to ~97% and ~98% purity respectively (Fig 1). Genomic DNA was isolated
from tumour and germline cells for WES.
Exome library sequencing yielded an average depth of 120-134x with 88–90% of target
bases covered by 20 or more reads (Table 4). An additional 63 novel nonsynonymous SVs,
with a range of 6–25 variants per tumour, were identified in the 5 HCLc exomes (Table 2). Fol-
lowing comprehensive bioinformatics analysis,>30% of randomly selected putative SVs were
re-sequenced by Sanger protocols, and these gave a 100% concordance to SV calls to establish
high confidence in the bioinformatic pipeline (data not shown). As expected, the BRAF V(600)
E mutation was identified in 5/5 HCLc exomes: significantly however, from our data no other
recurring mutations were apparent in these HCLc exomes (Table 3).
We evaluated potentially important SVs that occurred only in single individual HCLc
genomes in our data set. By structure-function prediction algorithms, the SV in the DUSP2
(dual specificity phosphatase 2) gene appears to be deleterious (Table 3), and DUSP2 encodes
an inhibitor of ERK in MAPK signalling, to suggest a potential role in potentiating constitutive
activation of the MAPK pathway in some HCLc cases. SVs in CHD7 (chromodomain helicase
DNA binding protein 7), SCD5 (stearoyl-CoA desaturase 5), SLC22A8 (solute carrier family
22, member 8), and CLEC6A (C-type lectin domain family 6, member A) had mutant allele fre-
quencies and corresponding significance levels that were comparable to or more significant
than BRAF V(600)E (somatic p-value1.15x10-21, Table 3), pointing to additional drivers that
may only occur sporadically in some cases in this form of disease.
The HCLc 5T case has just over twice as many variants as any other sample (22 versus10
SVs) which may be a consequence of a SV in POLD2 (polymerase [DNA directed], delta 2,
accessory subunit) which plays a critical role in DNA replication and repair.
Next we compared our findings of SVs with reported HCL exomes. We identified SVs in
CNTNAP4 (contactin associated protein-like 4), SLC22A24 (solute carrier family 22, member
24), and SLC22A8 that are in the same gene family as CNTN6 (contactin 6) and SLC5A1 (solute
carrier family 5, member 1), which were also reported by Tiacci et al in their single HCLc
exome study [8]. However, CNTNAP4 has low expression and late replication that suggests a
high rate of somatic mutation and the mutation is predicted to be neutral (Table 3).
Interestingly, very recently data on 3 exomes in pre-treated HCLc have been reported, in
which mutations in CDKN1B were found in 2/3 exomes, in addition to the expected BRAF V
(600)E [32]. By extending analysis of CDKN1B by conventional PCR-based Sanger sequencing
means, mutations in this gene were identified in presentation HCLc disease in 10/43 (23%)
cases [32]. CDKN1B (p27) is an important cell cycle control protein, and in this extended
screen, specific mutations in CDKN1B largely differed between individual HCLc patients [32].
In our exome data, we identified a single case (5T) with a CDKN1B (C>G p.T198R) mutation
(Table 3), differing to the panel of reported CDKN1Bmutations [32]. Additionally, we identi-
fied a mutation in the ABCC1 gene (ATP-binding cassette, sub-family C member 1) in Case 5T
(Table 3), which matches a mutation in the same functional pathway in ABCA8 gene (ATP-
binding cassette, sub-family A member 8) in a pre-treated HCLc case [32], suggesting occur-
rence prior to therapy and another potential recurrent gene mutation in HCLc disease.
We also observed a further 3 SVs in HCLc that were reported in atypical HCLv-HCLc/
IGHV4-34 exomes [13], in CREBBP, KIAA1755 andMUC5B (Table 3). Of these, CREBBP and
KIAA1755 have more significant somatic p-values in our data, but only the CREBBP variant is
predicted to be deleterious (Table 3). CREBBP encodes a CREB-binding protein, and is one of
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the earliest epigenetic modifiers that have been described and functions in chromatin remodel-
ling, acetylation and as a scaffold for transcription proteins [33]. KIAA1755 andMUC5Bmuta-
tions are predicted to be neutral (Table 3). These shared mutations may nevertheless be
indicative of shared selective events in specific gene circuits to promote onset of both subtypes
of disease.
Comparing our data on exomes in HCLc with the solitary exome reported by Tiacci et al [8]
and the 3 exomes reported in pre-treated HCLc [32], genes in the solute carrier (SLC) and
ATP-binding cassette (ABC) families may occur more frequently in presentation HCLc disease,
and appear to warrant further evaluation by conventional screening in larger cohorts.
Discussion
Our exome data now establish BRAF V(600)E as the sole near-universal mutation in presenta-
tion HCLc disease, not previously evident from a single exome study [8]. The data, by obviating
other highly penetrant mutations, place BRAF V(600)E at the centre of the aberrant molecular
drive in the pathogenesis and progression in HCLc. It may also explain the exquisite sensitivity
of HCLc to Vemurafenib, a targeted inhibitor of mutant BRAF in the clinic [34].
Other recurrent mutations may nevertheless prevail in smaller subsets of HCLc disease.
CDKN1B gene mutations have now been identified as present in treatment naive HCLc disease
in ~23% of cases [32]. Following our comparison of exome mutations in HCL, it is plausible
that mutations in the ABC and SLC gene families may emerge more frequently in cohort
screens, to establish specific HCLc subtypes stratified by shared common mutations in addition
to BRAF V(600)E. However, it appears highly unlikely that they will occur at near-universal
levels akin to BRAF V(600)E in HCLc, given that 6 exomes have now been evaluated in presen-
tation disease (our data & Tiacci et al [8]). In HCLc disease therefore, these data obviate a role
for other universal mutation(s) in pathogenesis. Small subsets of HCLc in which other gene
mutation(s) are recurrent and are shown to have a driver association may then plausibly com-
bine with mutant BRAF to further progress malignancy. Other individual HCLc tumours that
display distinct gene mutations that differ entirely between patients may conceptually harbour
specific driver mutations that could also co-operate with mutant BRAF to promote malignant
transformation. The pathways to pathogenesis of HCLc as revealed by exome data conse-
quently appear heterogeneous and varied. It is also noteworthy that in ~50% of HCLv and
HCLc/IGHV4-34 cases, exome data has thus far not identified any common somatic mutations
[13], and in these atypical HCL tumours, mutant gene pathways that drive pathogenesis of
atypical HCL disease also appear to differ markedly between individual tumours, and are cur-
rently not defined.
Our observation that some SVs in HCLc are also found in HCLv-HCLc/IGHV4-34 exomes
[13], in CREBBP, KIAA1755 andMUC5B, if verified in larger cohorts of both disease subtypes
may reveal shared dysregulated molecular and cellular pathways that are common to origins of
HCLc and atypical HCL disease.
Overall, a striking feature is the emergence and relevance of single dominant driver muta-
tions in HCLc and HCLv-HCLc/IGHV4-34 disease. This is further illuminated when consider-
ing the known physiological substrate specificities for BRAF and MEK1 (product of the
MAP2K1 gene). BRAF is a member of the RAF family of cytosolic kinases, and only phosphor-
ylate MEK1/2 [14,15,35]. MEK1/2 kinases in turn mediate phosphorylation that is restricted to
ERK1/2, their only two kinase substrates known to date under any physiological condition
[14,15]. From these biochemical studies, the substrate specificities intimately link mutant
RAF-MEK-ERK drive to the pathogenesis of much of the spectrum of HCL disease. In HCLc,
mutant BRAF constitutively activates RAF-MEK-ERK signalling whereas in atypical HCL, it is
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mutant MEK1 that constitutively activates this pathway. HCL then emerges as an exemplar in
cancer of a specific cellular pathway in which genes that are directly functionally linked are
mutated in origins of heterogeneous disease subsets.
Examining the RAF-MEK-ERK protein kinases further, these are known to constitute a
well-defined and linked signal transduction module or linked enzymatic ‘cassette’ due to the
stringent substrate specificities of the RAF and MEK1/2 protein kinases. This linked ‘cassette’
is a global cellular mechanism that can transduce specific receptor-ligand signals initiated at
multiple subcellular sites, straddling the outer plasma membrane and different cellular micro-
compartments in relaying signals that end in orchestrating specific transcriptional cascades to
determine cell fate [36]. An example of receptor-ligand signals transduced by the RAF-ME-
K-ERK module include BCR-antigen interactions at the cell surface plasma membrane, in
which BRAF is the dominant kinase in transducing signals from the BCR to activate ERK1/2
[37]. Another example is the role of this module in mediating regulation of the epidermal
growth factor (EGF)-EGF receptor, either at the cell surface plasma membrane or intracellular
membranes of the endoplasmic reticulum [36]. A constitutively active RAF-MEK-ERK signal-
ling cassette thereby potentially confers a potent activating mechanism that can drive an array
of cellular pathways (reviewed fully in [36]), to progress growth, proliferation and survival in
HCL tumour cells. The goal now is to define these activated cellular pathways concisely and
examine if they differ between HCLc and atypical HCL disease. Since an identical BRAF V
(600)E is also found in other diverse lymphoid and solid tumours [16, 38], the activated mutant
RAF-MEK-ERK module may by analogy also be exploited by tumour cells to selectively by-
pass critical microenvironment receptor-ligand dependencies for survival in those neoplasms.
One of the receptor-ligand interactions relayed by RAF-MEK-ERK signalling is when the
BCR is cross-linked by antigen. BCR signals that are transduced by antigen ligation are known
to be critical to normal mature B-cell survival [39], but the role of the BCR in malignant HCLc
persistence, if any, is as yet not fully defined. HCLc unusually displays multiple pre- and post-
isotype switched surface IgM/D/G/A in differing combinations on the same tumour cell [20],
and whether each isotype retained functionality in tumour cells had until recently remained
unknown. We undertook an evaluation of BCR function in HCLc cells, dissecting the role of
individual isotypes, and found unexpectedly that non-IgD isotypes that cross-link the BCR
directly trigger apoptosis of tumour cells ex-vivo [18]. These data suggested that BCR signals
conveyed by non-IgD isotypes are unlikely to support survival of tumour cells. The data also
infer that constitutive RAF-MEK-ERK signalling due to BRAF V(600)E is unlikely to be
required to supplant or by-pass any ligand (antigen) driven BCR-mediated dependency on
non-IgD isotypes in HCLc disease. It lends a further complexity as to why multiple isotypes are
expressed and retained by individual HCL tumour cells during the course of disease [20].
It is nevertheless now clear from exome data that mutant RAF-MEK-ERK signalling is a
central driver mechanism in the pathogenesis and progression of a wide spectrum of HCL dis-
ease. Strikingly, the BRAF V(600)E mutation has also now been identified in haematopoietic
stem cells (HSCs) in HCLc patients [40], revealing acquisition of this signature mutation at a
progenitor stage prior to commitment to the B-cell lineage. Despite acquisition of this potent
constitutively activated RAF-MEK-ERK pathway in HSCs, current molecular data suggests
that malignant transformation occurs in HCLc disease late at the mature B-cell stage, to impli-
cate distinctive pathways of B-cell maturation. Normal B-cells diversify on encounter with anti-
gen when recognised by the BCR to initiate differentiation. In T-cell dependent responses to
antigen, B-cells can seed a germinal centre (GC) in which SHM is initiated during a massive
blast phase to target IGV genes, with the aim of improving fit for antigen, and deletional CSR
can follow to alter isotype function [41]. Importantly, human memory B-cells that arise from
the GC acquire expression of CD27, a robust marker of GC trafficking [42]. In our previous
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work, we had delineated that neoplastic arrest in HCLc most likely occurs at a stage of B-cell
differentiation that straddles onset of SHM and deletional CSR [20,43], and as HCLc tumour
cells do not express CD27 [1], suggests that SHM and CSR may occur at ectopic sites in origins
of disease [44]. From this, it appears that antigen driven responses in the periphery may be a
vital pre-requisite in initiatingmalignant transformation in HCLc disease, but may not be
required in tumour persistence, as suggested by our study of BCR isotype function [18].
Significantly, mutant BRAF V(600)E has also been identified in HSCs from patients with
Langerhans cell histiocytosis (LCH) [45], a condition characterised by pathological accumula-
tion of CD207+dendritic cells to indicate that this lesion in HSCs can also drive clonal prolifer-
ation in the myeloid cell compartment. Interestingly, onset of LCH has been shown to
associate with response to inflammation by dendritic cell progenitors [45], revealing again that
normal immune responses are potent driver mechanisms in generating malignant proliferative
states from HSC progenitors bearing BRAF V(600)E [40,45]. Further stark parallels to HCL
disease have also emerged in LCH in relation to the type of somatic mutations found in tumour
cells. In LCH disease with wild type BRAF, recurrent mutations in theMAP2K1 gene can be
found in up to 50% of cases [46,47], substantiating a role for mutant RAF-MEK-ERK drive,
either via BRAF V(600)E or mutatedMAP2K1 in LCH pathogenesis.
The findings of BRAF V(600)E in HCLc and LCH stem cells also suggests that early selec-
tion pressure appears to be operative in funnelling stem cells bearing mutant BRAF to differing
cellular lineages. In both malignancies, inflammation-linked responses of lymphoid and mye-
loid progenitors harbouring mutated BRAF appear to be a critical factor in initiating malig-
nancy, for which there is evidence from knock-in models in LCH [45], but not as yet in HCLc.
These pathways also begin to resemble pathogenesis of solid tumours where mutant BRAF in
progenitor cells is insufficient to induce full-blown malignancy [16], and additional driver
events may well also derive from inflammation-associated interactions with precursor cells,
such as those implicated in colorectal cancer [48].
In HCLc specifically then, identifying which additional cellular pathways are aberrantly dys-
regulated and to what extent, orchestrated by specific genetic mutations and lesions, and how
they coalesce with mutant RAF-MEK-ERK drive imparted by BRAF V(600)E will unravel a full
understanding of malignant origins.
Acknowledgments
Exome sequencing was carried out at the Wellcome Trust Centre for Human Genetics, Oxford
(UK).
Author Contributions
Conceived and designed the experiments: SSS NJWB. Performed the experiments: NJWB. Ana-
lyzed the data: NJWBWT JG DB YMMJ ARC SSS. Contributed reagents/materials/analysis
tools: MJ SE HCKN. Wrote the paper: SSS NJWBWT JGMJ ARC.
References
1. Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol
Oncol. 2011: 29; 55–66. doi: 10.1002/hon.975 PMID: 21674564
2. Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat
Rev Cancer. 2006: 6; 437–448. PMID: 16723990
3. Kreitman RJ, WilsonW, Calvo KR, Arons E, Roth L, Sapolsky J, et al. Cladribine with immediate rituxi-
mab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res. 2013: 19; 6873–
6881. doi: 10.1158/1078-0432.CCR-13-1752 PMID: 24277451
HCLc ExomeMutations
PLOS ONE | DOI:10.1371/journal.pone.0149162 February 12, 2016 12 / 14
4. Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ (2001). The Occurrence
and Significance of V Gene Mutations in B Cell-Derived Human Malignancy. Adv. Cancer Research.
2011: 83;81–116.
5. Lefranc MP. Immunoglobulins: 25 years of immunoinformatics and IMGT-ONTOLOGY. Biomolecules.
2014: 4; 1102–39. doi: 10.3390/biom4041102 PMID: 25521638
6. Forconi F, Sozzi E, Rossi D, Sahota SS, Amato T, Raspadori D, et al. Selective influences in the
expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica.
2008: 93; 697–705. doi: 10.3324/haematol.12282 PMID: 18387977
7. Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with
poor prognosis despite standard therapy. Blood. 2009: 114; 4687–4695. doi: 10.1182/blood-2009-01-
201731 PMID: 19745070
8. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAFmutations in hairy-cell
leukemia. N Engl J Med. 2011: 364; 2305–2315. doi: 10.1056/NEJMoa1014209 PMID: 21663470
9. Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A, et al. Simple genetic diagnosis of
hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012: 119; 192–195.
doi: 10.1182/blood-2011-08-371179 PMID: 22028477
10. Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M, et al. The BRAF V600Emutation in
hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012: 119; 188–191. doi: 10.1182/
blood-2011-08-368209 PMID: 22072557
11. Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, et al. Both variant and IGHV4-34-
expressing hairy cell leukemia lack the BRAF V600Emutation. Blood. 2012: 119; 3330–3332. doi: 10.
1182/blood-2011-09-379339 PMID: 22210875
12. Laurini JA, Aoun P, Iqbal J, ChanW, Greiner TC. Investigation of the BRAF V600Emutation by pyrose-
quencing in lymphoproliferative disorders. Am J Clin Pathol. 2012: 138; 877–883. doi: 10.1309/
AJCP5TWORA0TMXGL PMID: 23161722
13. Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, et al. High prevalence of MAP2K1 muta-
tions in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014: 46; 8–10. doi: 10.
1038/ng.2828 PMID: 24241536
14. Roskoski R Jr. ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacological Research.
2012: 66; 105–143. doi: 10.1016/j.phrs.2012.04.005 PMID: 22569528
15. Roskoski R Jr. MEK1/2 dual-specificity protein kinases: structure and regulation. Biochem Biophys Res
Commun. 2012: 417; 5–10. doi: 10.1016/j.bbrc.2011.11.145 PMID: 22177953
16. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004: 6; 313–319.
PMID: 15488754
17. Kluin-Nelemans HC, Krouwels MM, Jansen JH, Dijkstra K, van Tol MJ, den Ottolander GJ et al. Hairy
cell leukemia preferentially expresses the IgG3-subclass. Blood. 1990: 75; 972–975. PMID: 2137355
18. Weston-Bell NJ, Forconi F, Kluin-Nelemans HC, Sahota SS. Variant B cell receptor isotype functions
differ in hairy cell leukemia with mutated BRAF and IGHV genes. PLoS One. 2014: 9; e86556. doi: 10.
1371/journal.pone.0086556 PMID: 24497953
19. Weston-Bell NJ, Hendriks D, Sugiyarto G, Bos NA, Kluin-Nelemans HC, Forconi F, et al. Hairy cell leu-
kemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary
tumour cells lack the signature BRAFmutation to reveal unrepresentative origins. Leukemia. 2013: 27;
241–245. doi: 10.1038/leu.2012.163 PMID: 22705994
20. Forconi F, Sahota SS, Raspadori D, Mockridge CI, Lauria F, Stevenson FK. Tumor cells of hairy cell
leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood. 2001: 98;
1174–1181. PMID: 11493467
21. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformat-
ics. 2010: 26; 841–842. doi: 10.1093/bioinformatics/btq033 PMID: 20110278
22. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. 1000 Genome Project Data Process-
ing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009: 25; 2078–
2079.
23. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and
copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012: 22; 568–576.
doi: 10.1101/gr.129684.111 PMID: 22300766
24. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-through-
put sequencing data. Nucleic Acids Res. 2010: 38; e164. doi: 10.1093/nar/gkq603 PMID: 20601685
25. Fuentes Fajardo KV, Adams D, Mason CE, Sincan M, Tifft C, Toro C, et al. Detecting false-positive sig-
nals in exome sequencing. HumMutat. 2012: 33; 609–613. doi: 10.1002/humu.22033 PMID:
22294350
HCLc ExomeMutations
PLOS ONE | DOI:10.1371/journal.pone.0149162 February 12, 2016 13 / 14
26. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heteroge-
neity in cancer and the search for new cancer-associated genes. Nature. 2013: 499; 214–218. doi: 10.
1038/nature12213 PMID: 23770567
27. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance
genomics data visualization and exploration. Brief Bioinform. 2013: 14; 178–192. doi: 10.1093/bib/
bbs017 PMID: 22517427
28. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server
for predicting damaging missense mutations. Nat Methods. 2010: 7; 248–249. doi: 10.1038/
nmeth0410-248 PMID: 20354512
29. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using
DAVID Bioinformatics Resources. Nature Protoc. 2009: 4; 44–57.
30. Seshan VE, Olshen A. DNAcopy: DNA copy number data analysis. R package version 1.20.0. 2010.
31. Jun G, Flickinger M, Hetrick KN, Romm JM, Doheny KF, Abecasis GR, et al. Detecting and estimating
contamination of human DNA samples in sequencing and array-based genotype data. Am J Hum
Genet. 2012: 91; 839–848. doi: 10.1016/j.ajhg.2012.09.004 PMID: 23103226
32. Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, et al. Recurrent CDKN1B (p27) mutations
in hairy cell leukemia. Blood. 2015: 126; 1005–1008. doi: 10.1182/blood-2015-04-643361 PMID:
26065650
33. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell. 2014: 5; 265–296.
doi: 10.1007/s13238-014-0031-6 PMID: 24622842
34. Dietrich S, GlimmH, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell
leukemia. N Engl J Med. 2012: 366; 2038–2040. doi: 10.1056/NEJMc1202124 PMID: 22621641
35. Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, et al. Raf family kinases:
old dogs have learned new tricks. Genes Cancer. 2011: 2; 232–260. doi: 10.1177/1947601911407323
PMID: 21779496
36. Kholodenko BN, Hancock JF, Kolch W. Signalling ballet in space and time. Nat Rev Mol Cell Biol. 2010:
11; 414–426. doi: 10.1038/nrm2901 PMID: 20495582
37. Brummer T, Shaw PE, Reth M, Misawa Y. Inducible gene deletion reveals different roles for B-Raf and
Raf-1 in B-cell antigen receptor signalling. EMBO J. 2002: 21; 5611–5622. PMID: 12411479
38. Mullighan CG. Genome sequencing of lymphoid malignancies. Blood. 2013: 122; 3899–3907. doi: 10.
1182/blood-2013-08-460311 PMID: 24041576
39. Lam KP, Kühn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible
gene targeting results in rapid cell death. Cell. 1997: 90; 1073–1083. PMID: 9323135
40. Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, et al. Hematopoietic stem cell origin
of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med. 2014: 6(238):238ra71. doi: 10.1126/
scitranslmed.3008004 PMID: 24871132
41. MacLennan IC. Germinal centers. Annual Review of Immunology. 1994: 12;117–139. PMID: 8011279
42. Klein U, Rajewsky K, Küppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells express-
ing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general
marker for somatically mutated (memory) B cells. The Journal of Experimental Medicine. 1998:
188;1679–1689. PMID: 9802980
43. Forconi F, Sahota SS, Raspadori D, Ippoliti M, Babbage G, Lauria F, et al. Hairy cell leukemia: at the
crossroad of somatic mutation and isotype switch. Blood. 2004: 104:3312–3317. PMID: 15284115
44. Weston-Bell N, Townsend M, Di Genova G, Forconi F, Sahota SS. Defining origins of malignant B-
cells: a new circulating normal human IgM+D+ B-cell subset lacking CD27 expression and displaying
somatically mutated IGVH genes as a relevant memory population. Leukemia. 2009: 23;2075–80. doi:
10.1038/leu.2009.178 PMID: 19776762
45. Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, et al. BRAF-V600E expression in precur-
sor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014:
211;669–683. doi: 10.1084/jem.20130977 PMID: 24638167
46. Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, et al. Mutually exclusive recur-
rent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH patho-
genesis. Blood. 2014: 124:3007–3015. doi: 10.1182/blood-2014-05-577825 PMID: 25202140
47. Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, et al. High prevalence of somatic
MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014: 124:1655–
1658. doi: 10.1182/blood-2014-05-577361 PMID: 24982505
48. Wang K, Karin M. Tumor-Elicited Inflammation and Colorectal Cancer. Adv Cancer Res. 2015:
128;173–96. doi: 10.1016/bs.acr.2015.04.014 PMID: 26216633
HCLc ExomeMutations
PLOS ONE | DOI:10.1371/journal.pone.0149162 February 12, 2016 14 / 14
